ArticleThe Journal of pharmacology and experimental therapeutics2011
Drug discontinuation effects are part of the pharmacology of a drug.
Article in The Journal of pharmacology and experimental therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Drug tapering in animal research: current practices and challenges.Frontiers in pharmacology · 2025Pooled it
- Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2020Pooled it
- Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo.Journal of the American Heart Association · 2026Trial
- Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine.Human psychopharmacology · 2026Review
- Pharmacological principles for safe benzodiazepine and Z-drug dose reduction.Psychological medicine · 2026Review
- Hospital readmissions related to adverse drug withdrawal events in older adults: a pilot study.International journal of clinical pharmacy · 2026Article
- Clinical Pharmacology of Heart Failure in Frailty.European cardiology · 2026Review
- Clozapine withdrawal catatonia: A case report.Indian journal of psychiatry · 2023Article
- Review
- Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure.European journal of clinical pharmacology · 2022Article
- Deprescribing trials: A focus on adverse drug withdrawal events.Journal of the American Geriatrics Society · 2022Article
- High levels of benzodiazepines after treatment of moderate alcohol withdrawal syndrome: the problem of incomplete detoxification.Postepy psychiatrii neurologii · 2022Article
- Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking.European journal of clinical pharmacology · 2022Article
- Priorities for future research on reducing and stopping psychiatric medicines using a James Lind Alliance priority setting partnership: The PROTECT study protocol.HRB open research · 2022Article
- Mobile phone applications to support psychotropic tapering: a scoping review protocol.HRB open research · 2022Article
- A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.Schizophrenia bulletin · 2021Article
- Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.European journal of clinical pharmacology · 2021Review
- Avoiding Adverse Drug Withdrawal Events When Stopping Unnecessary Medications According to the STOPPFrail Criteria.The Senior care pharmacist · 2021Article
- Blood Pressure Changes in 1610 Subjects With and Without Antihypertensive Medication During Long-Term Fasting.Journal of the American Heart Association · 2020Observational
- Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Most reviews of drug withdrawal effects focus on drugs of potential abuse such as opioids, benzodiazepines, etc. Abrupt discontinuation of many other drugs used in medicine cause withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase risk of cardiovascular events above that of people not taking these drugs. These include β-adrenergic receptor antagonists, aspirin, HMG-CoA reductase inhibitors (statins), and heparin. Rebound hypertension occurs after abrupt cessation of many antihypertensive drugs. The possibility of discontinuation syndromes has usually been neglected until adverse clinical events force them to be noticed. Attention to the possibility of drug discontinuation effects is an important part of drug safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.